E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2017
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2017
SUMMARY
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H2 2017, outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Leukemias, Osteosarcoma, Refractory Multiple Myeloma, Soft Tissue Sarcoma, Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Dedifferentiated Liposarcoma, Dry (Atrophic) Macular Degeneration, Essential Thrombocythemia, Follicular Lymphoma, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Vitreoretinopathy (PVR), Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma and Well Differentiated Liposarcoma.
Furthermore, this report also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H2 2017, outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Leukemias, Osteosarcoma, Refractory Multiple Myeloma, Soft Tissue Sarcoma, Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Dedifferentiated Liposarcoma, Dry (Atrophic) Macular Degeneration, Essential Thrombocythemia, Follicular Lymphoma, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Vitreoretinopathy (PVR), Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma and Well Differentiated Liposarcoma.
Furthermore, this report also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
- The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
- The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
Amgen Inc
Ascentage Pharma Group Corp Ltd
Boehringer Ingelheim GmbH
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Novartis AG
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles
ALRN-6924 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-7209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-0252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGM-097 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-50 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-3032 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-5272 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HDM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISA-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MI-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMRi-64 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-8994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit E3 Ubiquitin-Protein Ligase Mdm2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mdm2 and MdmX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MDMX and MDM2 for Solid and Liquid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-5272 at ASH
Nov 01, 2017: Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
Aug 24, 2017: Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
Jun 03, 2017: Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
May 18, 2017: Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53
Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology
Nov 30, 2016: Daiichi Sankyo Highlights Clinical Data on DS-3032 at the 58th Annual Meeting of the American Society of Hematology
Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53
Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
Amgen Inc
Ascentage Pharma Group Corp Ltd
Boehringer Ingelheim GmbH
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Novartis AG
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles
ALRN-6924 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-7209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-0252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGM-097 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-50 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-3032 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-5272 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HDM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISA-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MI-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMRi-64 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-8994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit E3 Ubiquitin-Protein Ligase Mdm2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MDM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mdm2 and MdmX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit MDMX and MDM2 for Solid and Liquid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-5272 at ASH
Nov 01, 2017: Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
Aug 24, 2017: Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
Jun 03, 2017: Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
May 18, 2017: Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53
Dec 05, 2016: Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology
Nov 30, 2016: Daiichi Sankyo Highlights Clinical Data on DS-3032 at the 58th Annual Meeting of the American Society of Hematology
Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53
Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aileron Therapeutics Inc, H2 2017
Pipeline by Amgen Inc, H2 2017
Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
Pipeline by Boehringer Ingelheim GmbH, H2 2017
Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by Novartis AG, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Dormant Products, H2 2017 (Contd.2), H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aileron Therapeutics Inc, H2 2017
Pipeline by Amgen Inc, H2 2017
Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
Pipeline by Boehringer Ingelheim GmbH, H2 2017
Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by Novartis AG, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Dormant Products, H2 2017 (Contd.2), H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Aileron Therapeutics Inc
Amgen Inc
Ascentage Pharma Group Corp Ltd
Boehringer Ingelheim GmbH
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Novartis AG
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Aileron Therapeutics Inc
Amgen Inc
Ascentage Pharma Group Corp Ltd
Boehringer Ingelheim GmbH
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Novartis AG
